Study title: Phase III Onchocerciasis - A Single-Blind, Placebo-Controlled Study of the Tolerability, Safety, and Efficacy of Successive Single Oral Doses of Ivermectin (MK-933). Approximately 150 to 220 mcg/kg in Adults with Onchocerciasis .
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Parasitic Diseases | |||||
Brands: Please see report, Please see report, Please see report | |||||
MAH holders: Please see report, Please see report, Please see report | |||||
Assessment: | |||||
Active substance: IVERMECTIN | |||||
ATC code: P02CF01 | |||||
Document link: Stromectol_Ivermectin_548_Synopsis.pdf | |||||
Document date: 2011-10-17 | |||||
Study number: Protocol J-21 548 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | - |